These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 34073710)
41. Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis. Crippa JA; Hallak JE; Abílio VC; de Lacerda AL; Zuardi AW CNS Neurol Disord Drug Targets; 2015; 14(8):970-8. PubMed ID: 26350340 [TBL] [Abstract][Full Text] [Related]
42. Aberrant high frequency oscillations recorded in the rat nucleus accumbens in the methylazoxymethanol acetate neurodevelopmental model of schizophrenia. Goda SA; Olszewski M; Piasecka J; Rejniak K; Whittington MA; Kasicki S; Hunt MJ Prog Neuropsychopharmacol Biol Psychiatry; 2015 Aug; 61():44-51. PubMed ID: 25862088 [TBL] [Abstract][Full Text] [Related]
43. Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia. Sonnenschein SF; Grace AA Neuropharmacology; 2020 Feb; 163():107632. PubMed ID: 31077730 [TBL] [Abstract][Full Text] [Related]
44. Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model. Horska K; Skrede S; Kucera J; Kuzminova G; Suchy P; Micale V; Ruda-Kucerova J CNS Neurosci Ther; 2024 Feb; 30(2):e14565. PubMed ID: 38421095 [TBL] [Abstract][Full Text] [Related]
45. Does cannabidiol have a role in the treatment of schizophrenia? Gururajan A; Malone DT Schizophr Res; 2016 Oct; 176(2-3):281-290. PubMed ID: 27374322 [TBL] [Abstract][Full Text] [Related]
46. Iloperidone for the treatment of schizophrenia. Marino J; Caballero J Ann Pharmacother; 2010 May; 44(5):863-70. PubMed ID: 20388862 [TBL] [Abstract][Full Text] [Related]
48. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. Szewczak MR; Corbett R; Rush DK; Wilmot CA; Conway PG; Strupczewski JT; Cornfeldt M J Pharmacol Exp Ther; 1995 Sep; 274(3):1404-13. PubMed ID: 7562515 [TBL] [Abstract][Full Text] [Related]
49. Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke. Ceprián M; Jiménez-Sánchez L; Vargas C; Barata L; Hind W; Martínez-Orgado J Neuropharmacology; 2017 Apr; 116():151-159. PubMed ID: 28012949 [TBL] [Abstract][Full Text] [Related]
50. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. Potkin SG; Litman RE; Torres R; Wolfgang CD J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S4-11. PubMed ID: 18334911 [TBL] [Abstract][Full Text] [Related]
51. α7 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia. Neves GA; Grace AA Neuropsychopharmacology; 2018 Jul; 43(8):1712-1720. PubMed ID: 29695783 [TBL] [Abstract][Full Text] [Related]
52. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914 [TBL] [Abstract][Full Text] [Related]
53. Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Albers LJ; Musenga A; Raggi MA Expert Opin Investig Drugs; 2008 Jan; 17(1):61-75. PubMed ID: 18095919 [TBL] [Abstract][Full Text] [Related]
54. Peripubertal mGluR2/3 Agonist Treatment Prevents Hippocampal Dysfunction and Dopamine System Hyperactivity in Adulthood in MAM Model of Schizophrenia. Sonnenschein SF; Grace AA Schizophr Bull; 2021 Oct; 47(6):1806-1814. PubMed ID: 33928393 [TBL] [Abstract][Full Text] [Related]
55. Iloperidone for the treatment of schizophrenia: an updated clinical review. Weiden PJ Clin Schizophr Relat Psychoses; 2012 Apr; 6(1):34-44. PubMed ID: 22453868 [TBL] [Abstract][Full Text] [Related]
56. Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice. Sonego AB; Gomes FV; Del Bel EA; Guimaraes FS Behav Brain Res; 2016 Aug; 309():22-8. PubMed ID: 27131780 [TBL] [Abstract][Full Text] [Related]
57. Iloperidone: a new option for the treatment of schizophrenia. Cutler AJ Expert Rev Neurother; 2009 Dec; 9(12):1727-41. PubMed ID: 19951132 [TBL] [Abstract][Full Text] [Related]
58. The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis. Kopelli E; Samara M; Siargkas A; Goulas A; Papazisis G; Chourdakis M Psychiatry Res; 2020 Sep; 291():113246. PubMed ID: 32599446 [TBL] [Abstract][Full Text] [Related]
59. Cannabidiol Modulates the Motor Profile and NMDA Receptor-related Alterations Induced by Ketamine. Brakatselos C; Delis F; Asprogerakas MZ; Lekkas P; Tseti I; Tzimas PS; Petrakis EA; Halabalaki M; Skaltsounis LA; Antoniou K Neuroscience; 2021 Feb; 454():105-115. PubMed ID: 32950556 [TBL] [Abstract][Full Text] [Related]
60. Disruption of prefrontal cortical-hippocampal balance in a developmental model of schizophrenia: reversal by sulpiride. Belujon P; Patton MH; Grace AA Int J Neuropsychopharmacol; 2013 Apr; 16(3):507-12. PubMed ID: 23067577 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]